Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 12/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HNF4A | P41235 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CRHBP | P24387 | 1/20 | 0.31 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7054381 | 1.00 | RXRA (0.37) | RXRAALDH1A1HNF4AGAACRHBP | |
| SCHEMBL6542371 | 0.90 | ALDH1A1 (0.37) | RXRAALDH1A1HNF4AGAAGFER | |
| SCHEMBL6542368 | 0.90 | ALDH1A1 (0.37) | RXRAALDH1A1HNF4AGAAGFER | |
| SCHEMBL7048842 | 0.88 | RXRA (0.38) | RXRAALDH1A1GFERRAB9ASMN1; SMN2 | |
| SCHEMBL6542041 | 0.88 | RXRA (0.48) | RXRA | |
| SCHEMBL6542035 | 0.88 | RXRA (0.48) | RXRA | |
| SCHEMBL7048839 | 0.88 | RXRA (0.38) | RXRAALDH1A1GFERRAB9ASMN1; SMN2 | |
| SCHEMBL6542177 | 0.86 | RXRA (0.41) | RXRAALDH1A1GAA | |
| SCHEMBL6542180 | 0.86 | RXRA (0.41) | RXRAALDH1A1GAA | |
| SCHEMBL7052708 | 0.85 | RXRA (0.36) | RXRAALDH1A1GAAGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030083357-A1 | Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia | ORTHO MCNEIL PHARMACEUTICAL INC. | 2003-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083357-A1 | Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia | OAT, CPT1A, CYP27A1 | RXRA 793/4885ALDH1A1 643/4885HNF4A 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.